Anticancer Cellular Immunotherapies: Optimizing the Path from Bench to FDA Approval (White Paper)
April 7, 2021
Anticancer Cellular Immunotherapies: Optimizing the Path from Bench to FDA ApprovalFrom the whitepaper:A striking number of anticancer cellular immunotherapies, also commonly referred to as adoptive cellular therapies (ACT), are in various stages of development, either as monotherapies or in combination with other treatments. This burgeoning and evolving pipeline of anticancer agents has largely been fueled by our increased understanding of how the immune system destroys cancer cells. Several types of cancer cell therapies are now providing new options to cancer patients.This paper explores key elements that drug developers should take into consideration from early on in drug development, so that the chances for ultimate FDA approval can be optimized.
by Cello Health’s Joel Sandler and Giovanni Ciavarra.
Cancer Progress by Cello Health
May 4 – 6, 2021 | Register!